Cwm LLC Reduces Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)

Cwm LLC reduced its position in CRISPR Therapeutics AG (NASDAQ:CRSP – Get Rating) by 35.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 405 shares of the company’s stock after selling 226 shares during the period. Cwm LLC’s holdings in CRISPR Therapeutics were worth $26,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. HM Payson & Co. lifted its position in CRISPR Therapeutics by 500.0% during the third quarter. HM Payson & Co. now owns 480 shares of the company’s stock valued at $31,000 after purchasing an additional 400 shares in the last quarter. Country Trust Bank purchased a new position in CRISPR Therapeutics during the third quarter valued at $33,000. Wipfli Financial Advisors LLC purchased a new position in CRISPR Therapeutics during the third quarter valued at $41,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA lifted its position in CRISPR Therapeutics by 159.2% during the second quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 635 shares of the company’s stock valued at $39,000 after purchasing an additional 390 shares in the last quarter. Finally, Allworth Financial LP lifted its position in CRISPR Therapeutics by 21.0% during the second quarter. Allworth Financial LP now owns 737 shares of the company’s stock valued at $45,000 after purchasing an additional 128 shares in the last quarter. 71.51% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Royal Bank of Canada decreased their price target on CRISPR Therapeutics from $79.00 to $70.00 and set a “sector perform” rating on the stock in a report on Wednesday, November 2nd. Citigroup decreased their price target on CRISPR Therapeutics from $83.00 to $63.00 and set a “neutral” rating on the stock in a report on Wednesday, November 23rd. Morgan Stanley assumed coverage on CRISPR Therapeutics in a report on Tuesday, October 11th. They set an “underweight” rating and a $37.00 price target on the stock. Barclays decreased their price target on CRISPR Therapeutics from $88.00 to $61.00 in a report on Wednesday, November 2nd. Finally, EF Hutton Acquisition Co. I assumed coverage on CRISPR Therapeutics in a report on Thursday, January 5th. They set a “buy” rating and a $75.00 price target on the stock. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $98.22.

Insider Buying and Selling at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 28th. The stock was sold at an average price of $40.93, for a total value of $1,023,250.00. Following the completion of the sale, the chief executive officer now owns 369,111 shares in the company, valued at $15,107,713.23. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 75,000 shares of company stock worth $3,744,250 over the last 90 days. Company insiders own 5.30% of the company’s stock.

CRISPR Therapeutics Price Performance

Shares of NASDAQ:CRSP opened at $49.61 on Friday. CRISPR Therapeutics AG has a 1 year low of $38.94 and a 1 year high of $86.95. The business has a 50 day simple moving average of $49.65 and a two-hundred day simple moving average of $61.00. The firm has a market capitalization of $3.88 billion, a PE ratio of -5.64 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP – Get Rating) last announced its earnings results on Tuesday, November 1st. The company reported ($2.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.30) by $0.06. CRISPR Therapeutics had a negative return on equity of 31.34% and a negative net margin of 4,831.79%. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $3.53 million. Equities research analysts expect that CRISPR Therapeutics AG will post -9.23 EPS for the current fiscal year.

CRISPR Therapeutics Company Profile

(Get Rating)

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.